Investment in Research, and Innovation is very Modest, Given the Magnitude of the Obesity Problem and its Economic Consequences
Investment in research, innovation, and experimentation is very modest, given the magnitude of the obesity problem and its economic consequences. The United Kingdom, for example, spends less than $1 billion a year on preventive efforts including weight-loss programmes and public health campaigns. To put it in context, it only accounts for approximately 1% of the societal cost of obesity in the UK. More money is needed, particularly to better understand the efficacy of intervention techniques when used as part of a larger programme. However, society should be willing to try out different treatments. Impact data from high-quality, randomised control studies is difficult to come by in many intervention areas. Rather of waiting for such evidence, relevant sections of society should be rational & take action where the risks of intervention are minimal.
Obesity is Being Driven by Social Shifts and a Global Dietary Revolution
The escalating pandemic reflects the significant changes in society and community behaviour patterns over the last several decades. While genes have a role in defining a person's vulnerability to weight gain, calorie intake and physical exercise influence energy balance. As a result, the obesity pandemic is being driven by social shifts and a global dietary revolution. Economic development, industrialization, urbanisation, and food market globalisation are just a few of the factors believed to be driving the pandemic.
Meals rich in complex carbohydrates give way to more diverse diets with a greater percentage of lipids, saturated fats, and sweets as wages increase and people become more urban. Simultaneously, significant changes toward less physically demanding employment have been seen across the globe. Increased use of automated transportation, technology in the house, and more passive leisure activities are all signs of a shift away from physical exercise.
Which Factors are Driving the Global Anti-Obesity Drugs Market?
• Rising Obesity Awareness to Fuel Market Growth
• Growing Healthcare Expenditure Anticipated to Drive Market Growth
What are the Market Opportunities for Global Anti-Obesity Drugs Market?
• Growing Obesity Consciousness Among Public to Offer Lucrative Growth Opportunities
• COVID-19 Pandemic Anticipated to Boost Market Growth
• Emerging Economies to Offer Lucrative Growth Prospects
Discover how to stay ahead
Our 500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anti-Obesity Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets
Mechanism of Action
• Incretin Mimetics/GLP-1 Agonists
• Lipase Inhibitors
• SNDRI’s
• Serotonin Receptor Agonists
• Sympathomimetic-GABA Receptor Agonists
• Sympathomimetics
• Others
Type
• Prescription Drugs
• OTC Drugs
Duration
• Short-Term Anti-Obesity Drugs
• Long-Term Anti-Obesity Drugs
Distribution Channel
• Hospitals
• Retail
• Online
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:
By Region
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
Leading companies and the potential for market growth
Overall world revenue for anti-obesity drugs market will surpass US$xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Anti-Obesity Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Anti-Obesity Drugs Market, with forecasts for mechanism of action, type, duration and distribution channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 18 key national markets– See forecasts for the Anti-Obesity Drugs market in North America, Europe, Asia Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, South Korea, South-East Asia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 17 of the companies involved in the Anti-Obesity Drugs Market. Some of the company’s profiled in this report include Bristol-Myers Squibb, Carmot Therapeutics, CohBar, Currax Pharmaceuticals LLC, Eisai Co. Ltd, ERX Pharmaceuticals, Gelesis, GlaxoSmithKline PLC, Hanmi Pharmaceutical, Co., Ltd., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Scohia Pharma, Inc., Saniona, Vivus Inc. and YSOPIA Bioscience among other prominent players.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Anti-Obesity Drugs Market and leading companies. You will find data, trends, and predictions.
'
1. Report Overview
1.1 Introduction to Anti-Obesity Drugs Market
1.2 Anti-Obesity Drugs Market Definition
1.3 Why You Should Read This Report
1.4 What This Report Delivers
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 COVID-19 Impact: Recovery Scenarios
1.7.2 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Rising Obesity Awareness to Fuel Market Growth
3.1.2 Growing Healthcare Expenditure Anticipated to Drive Market Growth
3.2 Restraints
3.2.1 Lack of Understanding
3.2.2 Lack of Insurance to Restrain Market Growth
3.2.3 Clinical Trial Enrolment Challenging Market Growth
3.3 Opportunities
3.3.1 Growing Obesity Consciousness Among Public to Offer Lucrative Growth Opportunities
3.3.2 COVID-19 Pandemic Anticipated to Boost Market Growth
3.3.3 Emerging Economies to Offer Lucrative Growth Prospects
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weaknesses
3.4.3 Opportunities
3.4.4 Threats
3.5 Porter’s Five Forces Analysis
3.5.1 Buyer Power
3.5.2 Supplier Power
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitute
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors Impacting Anti-Obesity Drugs Market
3.6.2 Economic Factors Impacting Anti-Obesity Drugs Market
3.6.3 Social Factors Impacting Anti-Obesity Drugs Market
3.6.4 Technological Factors Impacting Anti-Obesity Drugs Market
4 Anti-Obesity Drugs Market by Mechanism of Action
4.1 Incretin Mimetics/GLP-1 Agonists Segment Market Forecast, 2021-2031
4.1.1 Incretin Mimetics/GLP-1 Agonists Market Overview
4.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.2 Lipase Inhibitors Segment Market Forecast, 2021-2031
4.2.1 Lipase Inhibitors Market Overview
4.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.3 SNDRI’s Segment Market Forecast, 2021-2031
4.3.1 SNDRI’s Market Overview
4.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.4 Serotonin Receptor Agonists Segment Market Forecast, 2021-2031
4.4.1 Serotonin Market Overview
4.4.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.5 Sympathomimetic-GABA Receptor Agonists Segment Market Forecast, 2021-2031
4.5.1 Sympathomimetic-GABA Receptor Agonists Market Revenue, 2021-2031
4.5.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.6 Sympathomimetics Segment Market Forecast, 2021-2031
4.6.1 Sympathomimetic Market Overview
4.6.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.7 Others Segment Market Forecast, 2021-2031
4.7.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5 Anti-Obesity Drugs Market by Type
5.1 Prescription Drugs Segment Market Forecast, 2021-2031
5.1.1 Prescription Drugs Market Overview
5.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.2 OTC Drugs Segment Market Forecast, 2021-2031
5.2.1 OTC Drugs Market Overview
5.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6 Anti-Obesity Drugs Market by Duration
6.1 Short-Term Anti-Obesity Drugs Segment Market Forecast, 2021-2031
6.1.1 Short-Term Anti-Obesity Drugs Market Overview
6.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6.2 Long-Term Anti-Obesity Drugs Segment Market Forecast, 2021-2031
6.2.1 Long-Term Anti-Obesity Drugs Market Overview
6.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7 Anti-Obesity Drugs Market by Distribution Channel
7.1 Hospitals Segment Market Forecast, 2021-2031
7.1.1 Hospitals Segment Market Overview
7.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7.2 Retail Segment Market Forecast, 2021-2031
7.2.1 Retail Segment Market Overview
7.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7.3 Online Segment Market Forecast, 2021-2031
7.3.1 Online Segment Market Overview
7.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
8 Regional and Leading National Anti-Obesity Drugs Market Forecasts 2021-2031
8.1 Global Anti-Obesity Drugs Market by Region Forecast 2021-2031
8.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
9 North America Anti-Obesity Drugs Market
9.1 North America Anti-Obesity Drugs Market by Country, Forecast 2021-2031
9.2 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action
9.3 North America Anti-Obesity Drugs Market Forecast by Type
9.4 North America Anti-Obesity Drugs Market Forecast by Duration
9.5 North America Anti-Obesity Drugs Market Forecast by Distribution Channel
9.6 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031
9.6.1 U.S. Anti-Obesity Drugs Market Overview
9.6.2 U.S. Anti-Obesity Drugs Market Forecast to 2031
9.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Anti-Obesity Drugs Market Forecast, 2021-2031
9.7 Canada Anti-Obesity Drugs Market Forecast, 2021-2031
9.7.1 Canada Anti-Obesity Drugs Market Overview
9.7.2 Canada Anti-Obesity Drugs Market Forecast to 2031
9.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Anti-Obesity Drugs Market Forecast, 2021-2031
10 Europe Anti-Obesity Drugs Market
10.1 Europe Anti-Obesity Drugs Market by Country, Forecast 2021-2031
10.2 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action
10.3 Europe Anti-Obesity Drugs Market Forecast by Type
10.4 Europe Anti-Obesity Drugs Market Forecast by Duration
10.5 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel
10.6 Germany Anti-Obesity Drugs Market Forecast, 2021-2031
10.6.1 Germany Anti-Obesity Drugs Market Overview
10.6.2 Germany Anti-Obesity Drugs Market Forecast to 2031
10.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Anti-Obesity Drugs Market Forecast, 2021-2031
10.7 UK Anti-Obesity Drugs Market Forecast, 2021-2031
10.7.1 UK Anti-Obesity Drugs Market Overview
10.7.2 UK Anti-Obesity Drugs Market Forecast to 2031
10.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Anti-Obesity Drugs Market Forecast, 2021-2031
10.8 France Anti-Obesity Drugs Market Forecast, 2021-2031
10.8.1 France Anti-Obesity Drugs Market Overview
10.8.2 France Anti-Obesity Drugs Market Forecast to 2031
10.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Anti-Obesity Drugs Market Forecast, 2021-2031
10.9 Italy Anti-Obesity Drugs Market Forecast, 2021-2031
10.9.1 Italy Anti-Obesity Drugs Market Overview
10.9.2 Italy Anti-Obesity Drugs Market Forecast to 2031
10.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Anti-Obesity Drugs Market Forecast, 2021-2031
10.10 Spain Anti-Obesity Drugs Market Forecast, 2021-2031
10.10.1 Spain Anti-Obesity Drugs Market Overview
10.10.2 Spain Anti-Obesity Drugs Market Forecast to 2031
10.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Anti-Obesity Drugs Market Forecast, 2021-2031
10.11 Russia Anti-Obesity Drugs Market Forecast, 2021-2031
10.11.1 Russia Anti-Obesity Drugs Market Overview
10.11.2 Russia Anti-Obesity Drugs Market Forecast to 2031
10.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Russia Anti-Obesity Drugs Market Forecast, 2021-2031
10.12 Rest of Europe Anti-Obesity Drugs Market Forecast, 2021-2031
10.12.1 Rest of Europe Anti-Obesity Drugs Market Overview
10.12.2 Rest of Europe Anti-Obesity Drugs Market Forecast to 2031
10.12.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Anti-Obesity Drugs Market Forecast, 2021-2031
11 Asia Pacific Anti-Obesity Drugs Market
11.1 Asia Pacific Anti-Obesity Drugs Market by Country, Forecast 2021-2031
11.2 Asia Pacific Anti-Obesity Drugs Market Forecast by Mechanism of Action
11.3 Asia Pacific Anti-Obesity Drugs Market Forecast by Type
11.4 Asia Pacific Anti-Obesity Drugs Market Forecast by Duration
11.5 Asia Pacific Anti-Obesity Drugs Market Forecast by Distribution Channel
11.6 Japan Anti-Obesity Drugs Market Forecast, 2021-2031
11.6.1 Japan Anti-Obesity Drugs Market Overview
11.6.2 Japan Anti-Obesity Drugs Market Forecast to 2031
11.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Anti-Obesity Drugs Market Forecast, 2021-2031
11.7 China Anti-Obesity Drugs Market Forecast, 2021-2031
11.7.1 China Anti-Obesity Drugs Market Overview
11.7.2 China Anti-Obesity Drugs Market Forecast to 2031
11.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Anti-Obesity Drugs Market Forecast, 2021-2031
11.8 India Anti-Obesity Drugs Market Forecast, 2021-2031
11.8.1 India Anti-Obesity Drugs Market Overview
11.8.2 India Anti-Obesity Drugs Market Forecast to 2031
11.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Anti-Obesity Drugs Market Forecast, 2021-2031
11.9 Australia Anti-Obesity Drugs Market Forecast, 2021-2031
11.9.1 Australia Anti-Obesity Drugs Market Overview
11.9.2 Australia Anti-Obesity Drugs Market Forecast to 2031
11.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Australia Anti-Obesity Drugs Market Forecast, 2021-2031
11.10 South Korea Anti-Obesity Drugs Market Forecast, 2021-2031
11.10.1 South Korea Anti-Obesity Drugs Market Overview
11.10.2 South Korea Anti-Obesity Drugs Market Forecast to 2031
11.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Korea Anti-Obesity Drugs Market Forecast, 2021-2031
11.11 South-East Asia Anti-Obesity Drugs Market Forecast, 2021-2031
11.11.1 South-East Asia Anti-Obesity Drugs Market Forecast to 2031
11.11.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): South-East Asia Anti-Obesity Drugs Market Forecast, 2021-2031
11.12 Rest of Asia Pacific Anti-Obesity Drugs Market Forecast, 2021-2031
11.12.1 Rest of Asia Pacific Anti-Obesity Drugs Market Forecast to 2031
11.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Anti-Obesity Drugs Market Forecast, 2021-2031
12 Latin America Anti-Obesity Drugs Market
12.1 Latin America Anti-Obesity Drugs Market by Country, Forecast 2021-2031
12.2 Latin America Anti-Obesity Drugs Market Forecast by Mechanism of Action
12.3 Latin America Anti-Obesity Drugs Market Forecast by Type
12.4 Latin America Anti-Obesity Drugs Market Forecast by Duration
12.5 Latin America Anti-Obesity Drugs Market Forecast by Distribution Channel
12.6 Brazil Anti-Obesity Drugs Market Forecast, 2021-2031
12.6.1 Brazil Anti-Obesity Drugs Market Overview
12.6.2 Brazil Anti-Obesity Drugs Market Forecast to 2031
12.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Anti-Obesity Drugs Market Forecast, 2021-2031
12.7 Mexico Anti-Obesity Drugs Market Forecast, 2021-2031
12.7.1 Mexico Anti-Obesity Drugs Market Overview
12.7.2 Mexico Anti-Obesity Drugs Market Forecast to 2031
12.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Anti-Obesity Drugs Market Forecast, 2021-2031
12.8 Rest of Latin America Anti-Obesity Drugs Market Forecast, 2021-2031
12.8.1 Rest of Latin America Anti-Obesity Drugs Market Forecast to 2031
12.8.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Anti-Obesity Drugs Market Forecast, 2021-2031
13 Middle East and Africa Anti-Obesity Drugs Market
13.1 Middle East and Africa Anti-Obesity Drugs Market by Country, Forecast 2021-2031
13.2 MEA Anti-Obesity Drugs Market Forecast by Mechanism of Action
13.3 MEA Anti-Obesity Drugs Market Forecast by Type
13.4 MEA Anti-Obesity Drugs Market Forecast by Duration
13.5 MEA Anti-Obesity Drugs Market Forecast by Distribution Channel
13.6 GCC Anti-Obesity Drugs Market Forecast, 2021-2031
13.6.1 GCC Anti-Obesity Drugs Market Overview
13.6.2 GCC Anti-Obesity Drugs Market Forecast to 2031
13.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Anti-Obesity Drugs Market Forecast, 2021-2031
13.7 South Africa Anti-Obesity Drugs Market Forecast, 2021-2031
13.7.1 South Africa Anti-Obesity Drugs Market Overview
13.7.2 South Africa Anti-Obesity Drugs Market Forecast to 2031
13.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Anti-Obesity Drugs Market Forecast, 2021-2031
13.8 Rest of Middle East and Africa Anti-Obesity Drugs Market Forecast, 2021-2031
13.8.1 Rest of MEA Anti-Obesity Drugs Market Overview
13.8.2 Rest of MEA Anti-Obesity Drugs Market Forecast to 2031
13.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Anti-Obesity Drugs Market Forecast, 2021-2031
14 Company Profiles
14.1 Bristol-Myers Squibb
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.4 Product Benchmarking
14.1.5 Recent Developments
14.2 Currax Pharmaceuticals LLC
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.2.4 Recent Developments
14.3 Eisai Co. Ltd
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.4 Product Benchmarking
14.3.5 Recent Developments
14.4 GlaxoSmithKline PLC
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.4 Product Benchmarking
14.4.5 Recent Developments
14.5 Merck & Co. Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.4 Product Benchmarking
14.5.5 Recent Developments
14.6 Novo Nordisk A/S
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.4 Product Benchmarking
14.6.5 Recent Developments
14.7 Pfizer Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.4 Product Benchmarking
14.7.5 Recent Developments
14.8 Rhythm Pharmaceuticals
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.4 Product Benchmarking
14.8.5 Recent Developments
14.9 Vivus Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.4 Product Benchmarking
14.9.5 Recent Developments
14.10 ERX Pharmaceuticals
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.11 CohBar
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.4 Product Benchmarking
Recent Developments
14.12 Carmot Therapeutics
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.13 YSOPIA Bioscience
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Gelesis
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.15 Scohia Pharma, Inc.
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Product Benchmarking
14.16 Hanmi Pharmaceutical, Co., Ltd.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.4 Product Benchmarking
14.17 Saniona
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations for Market Players
List of Tables
Table 1 Global Anti-Obesity Drugs Market Snapshot, 2021 & 2031 (US$ million, CAGR %)
Table 2 Global Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 3 Global Anti-Obesity Drugs Market Forecast for Incretin Mimetics/GLP-1 Agonists Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 4 Global Anti-Obesity Drugs Market Forecast for Incretin Mimetics/GLP-1 Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 5 Global Anti-Obesity Drugs Market Forecast for Incretin Mimetics/GLP-1 Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 6 Global Anti-Obesity Drugs Market Forecast for Incretin Mimetics/GLP-1 Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 7 Global Anti-Obesity Drugs Market Forecast for Incretin Mimetics/GLP-1 Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 8 Global Anti-Obesity Drugs Market Forecast for Lipase Inhibitors Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 9 Global Anti-Obesity Drugs Market Forecast for Lipase Inhibitors Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 10 Global Anti-Obesity Drugs Market Forecast for Lipase Inhibitors Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 11 Global Anti-Obesity Drugs Market Forecast for Lipase Inhibitors Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 12 Global Anti-Obesity Drugs Market Forecast for Lipase Inhibitors Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 13 Global Anti-Obesity Drugs Market Forecast for SNDRI's Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 14 Global Anti-Obesity Drugs Market Forecast for SNDRI's Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 15 Global Anti-Obesity Drugs Market Forecast for SNDRI's Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 16 Global Anti-Obesity Drugs Market Forecast for SNDRI's Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 17 Global Anti-Obesity Drugs Market Forecast for SNDRI's Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 18 Global Anti-Obesity Drugs Market Forecast for Serotonin Receptor Agonists Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 19 Global Anti-Obesity Drugs Market Forecast for Serotonin Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 20 Global Anti-Obesity Drugs Market Forecast for Serotonin Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 21 Global Anti-Obesity Drugs Market Forecast for Serotonin Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 22 Global Anti-Obesity Drugs Market Forecast for Serotonin Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 23 Global Anti-Obesity Drugs Market Forecast for Sympathomimetic-GABA Receptor Agonists Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 24 Global Anti-Obesity Drugs Market Forecast for Sympathomimetic-GABA Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 25 Global Anti-Obesity Drugs Market Forecast for Sympathomimetic-GABA Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 26 Global Anti-Obesity Drugs Market Forecast for Sympathomimetic-GABA Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 27 Global Anti-Obesity Drugs Market Forecast for Sympathomimetic-GABA Receptor Agonists Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 28 Global Anti-Obesity Drugs Market Forecast for Sympathomimetics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 29 Global Anti-Obesity Drugs Market Forecast for Sympathomimetics Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 30 Global Anti-Obesity Drugs Market Forecast for Sympathomimetics Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 31 Global Anti-Obesity Drugs Market Forecast for Sympathomimetics Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 32 Global Anti-Obesity Drugs Market Forecast for Sympathomimetics Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 33 Global Anti-Obesity Drugs Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 34 Global Anti-Obesity Drugs Market Forecast for Others Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 35 Global Anti-Obesity Drugs Market Forecast for Others Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 36 Global Anti-Obesity Drugs Market Forecast for Others Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 37 Global Anti-Obesity Drugs Market Forecast for Others Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 38 Global Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 39 Global Anti-Obesity Drugs Market Forecast for Prescription Drugs Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 40 Global Anti-Obesity Drugs Market Forecast for Prescription Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 41 Global Anti-Obesity Drugs Market Forecast for Prescription Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 42 Global Anti-Obesity Drugs Market Forecast for Prescription Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 43 Global Anti-Obesity Drugs Market Forecast for Prescription Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 44 Global Anti-Obesity Drugs Market Forecast for OTC Drugs Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 45 Global Anti-Obesity Drugs Market Forecast for OTC Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 46 Global Anti-Obesity Drugs Market Forecast for OTC Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 47 Global Anti-Obesity Drugs Market Forecast for OTC Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 48 Global Anti-Obesity Drugs Market Forecast for OTC Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 49 Global Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 50 Global Anti-Obesity Drugs Market Forecast for Short-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 51 Global Anti-Obesity Drugs Market Forecast for Short-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 52 Global Anti-Obesity Drugs Market Forecast for Short-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 53 Global Anti-Obesity Drugs Market Forecast for Short-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 54 Global Anti-Obesity Drugs Market Forecast for Short-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 55 Global Anti-Obesity Drugs Market Forecast for Long-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 56 Global Anti-Obesity Drugs Market Forecast for Long-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 57 Global Anti-Obesity Drugs Market Forecast for Long-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 58 Global Anti-Obesity Drugs Market Forecast for Long-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 59 Global Anti-Obesity Drugs Market Forecast for Long-Term Anti-Obesity Drugs Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 60 Global Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 61 Global Anti-Obesity Drugs Market Forecast for Hospitals Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 62 Global Anti-Obesity Drugs Market Forecast for Hospitals Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 63 Global Anti-Obesity Drugs Market Forecast for Hospitals Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 64 Global Anti-Obesity Drugs Market Forecast for Hospitals Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 65 Global Anti-Obesity Drugs Market Forecast for Hospitals Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 66 Global Anti-Obesity Drugs Market Forecast for Retail Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 67 Global Anti-Obesity Drugs Market Forecast for Retail Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 68 Global Anti-Obesity Drugs Market Forecast for Retail Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 69 Global Anti-Obesity Drugs Market Forecast for Retail Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 70 Global Anti-Obesity Drugs Market Forecast for Retail Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 71 Global Anti-Obesity Drugs Market Forecast for Online Segment, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 72 Global Anti-Obesity Drugs Market Forecast for Online Segment, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 73 Global Anti-Obesity Drugs Market Forecast for Online Segment, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 74 Global Anti-Obesity Drugs Market Forecast for Online Segment, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 75 Global Anti-Obesity Drugs Market Forecast for Online Segment, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 76 Global Anti-Obesity Drugs Market Forecast by Region 2021-2031 (US$ mn, AGR%, CAGR%)
Table 77 Global Anti-Obesity Drugs Market Forecast by Region 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 78 Global Anti-Obesity Drugs Market Forecast by Region 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 79 Global Anti-Obesity Drugs Market Forecast by Region 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 80 Global Anti-Obesity Drugs Market Forecast by Region 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 81 North America Anti-Obesity Drugs Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 82 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 83 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 84 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 85 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 86 North America Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 87 North America Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 88 North America Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 89 North America Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 90 North America Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 91 North America Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 92 North America Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 93 North America Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 94 North America Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 95 North America Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 96 North America Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 97 North America Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 98 North America Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 99 North America Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 100 North America Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 101 North America Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 102 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 103 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 104 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 105 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 106 U.S. Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 107 Canada Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 108 Canada Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 109 Canada Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 110 Canada Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 111 Canada Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 112 Europe Anti-Obesity Drugs Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 113 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 114 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 115 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 116 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 117 Europe Anti-Obesity Drugs Market Forecast by Mechanism of Action, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 118 Europe Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 119 Europe Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 120 Europe Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 121 Europe Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 122 Europe Anti-Obesity Drugs Market Forecast by Prescription, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 123 Europe Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 124 Europe Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 125 Europe Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 126 Europe Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 127 Europe Anti-Obesity Drugs Market Forecast by Duration, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 128 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 129 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 130 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 131 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 132 Europe Anti-Obesity Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 133 Germany Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 134 Germany Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 135 Germany Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 136 Germany Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 137 Germany Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 138 UK Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
Table 139 UK Anti-Obesity Drugs Market Forecast, 2021-2031 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 140 UK An
